C-1 Gentamicin Composition Reducing Nephrotoxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current aminoglycoside antibiotics, such as gentamicin, exhibit high nephrotoxicity, limiting their use in treating bacterial infections and kidney-related issues due to renal toxicity, and existing methods fail to effectively separate and purify their congeners to reduce toxicity.
Innovation Solution
The development of a composition comprising the C-1 congener of gentamicin, formulated as a liquid with a preservative and chelating agent, substantially free of C-1a and C-2a gentamicin, which demonstrates lower nephrotoxicity and maintains effective antibacterial activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If native gentamicin is used to treat bacterial infections, then antibacterial activity is achieved, but nephrotoxicity increases
Solution Approach 1:
The patent separates gentamicin into its individual congener components (C-1, C-1a, C-2, C-2a) through chromatographic purification. This segmentation allows selection of the least toxic congener (C-1) while eliminating or reducing more toxic congeners, thereby resolving the contradiction between maintaining antibacterial activity and reducing nephrotoxicity
Solution Approach 2:
The patent applies local quality by creating a composition with specific congener composition (predominantly C-1 gentamicin with controlled amounts of other congeners). This localized modification of the chemical composition at the molecular level maintains the therapeutic antibacterial properties while reducing the harmful nephrotoxic effects associated with native gentamicin mixture
2Object-affected harmful factors
If gentamicin congeners are separated and purified to reduce toxicity, then nephrotoxicity decreases, but manufacturing complexity increases
Solution Approach 1:
The patent extracts the desired C-1 gentamicin congener from the native gentamicin mixture using chromatographic separation methods. This extraction process isolates the low-toxicity congener while removing or reducing the high-toxicity congeners, achieving toxicity reduction through selective removal of harmful components
Solution Approach 2:
The patent utilizes parameter changes in the chromatographic separation process (mobile phase composition, flow rate, temperature) to optimize the separation of gentamicin congeners. By adjusting these parameters, the manufacturing process achieves effective separation and purification of C-1 gentamicin while managing the complexity of the separation procedure
Data Source
AI summary
Various aspects relate to the use of C-1 gentamicin as an antibiotic effective for the treatment of a bacterial infection, a genetic disorder, or cancer in a subject.